Biological basis and treatment of frailty and sarcopenia
Cardiovascular Research · 31.07.2024 · 120 (9) · 982-998
DOI: 10.1093/cvr/cvae073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 03.06.2024. Verfasst von Ryosuke Sato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Str. 40, 37075 Göttingen, Germany. Hauptthemen laut MEDLINE: Sarcopenia, Frailty, Muscle, Skeletal, Frail Elderly. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 257 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
In an ageing society, the importance of maintaining healthy life expectancy has been emphasized. As a result of age-related decline in functional reserve, frailty is a state of increased vulnerability and susceptibility to adverse health outcomes with a serious impact on healthy life expectancy. The decline in skeletal muscle mass and function, also known as sarcopenia, is key in the development of physical frailty. Both frailty and sarcopenia are highly prevalent in patients not only with advanced age but also in patients with illnesses that exacerbate their progression like heart failure (HF), cancer, or dementia, with the prevalence of frailty and sarcopenia in HF patients reaching up to 50–75% and 19.5–47.3%, respectively, resulting in 1.5–3 times higher 1-year mortality. The biological mechanisms of frailty and sarcopenia are multifactorial, complex, and not yet fully elucidated, ranging from DNA damage, proteostasis impairment, and epigenetic changes to mitochondrial dysfunction, cellular senescence, and environmental factors, many of which are further linked to cardiac disease. Currently, there is no gold standard for the treatment of frailty and sarcopenia, however, growing evidence supports that a combination of exercise training and nutritional supplement improves skeletal muscle function and frailty, with a variety of other therapies being devised based on the underlying pathophysiology. In this review, we address the involvement of frailty and sarcopenia in cardiac disease and describe the latest insights into their biological mechanisms as well as the potential for intervention through exercise, diet, and specific therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
- German Center for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.
- Heart Institute (InCor), University of São Paulo Medical School, São Paulo, SP, Brazil.
- School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.
- Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
- Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
ORCID-Profile: Ryosuke Sato, Stefan D Anker, Stephan von Haehling
Zitieren
APA
Sato, R., Vatic, M., Peixoto da Fonseca, G. W., Anker, S. D., & von Haehling, S. (2024). Biological basis and treatment of frailty and sarcopenia. Cardiovascular Research, 120(9), 982-998. https://doi.org/10.1093/cvr/cvae073
Vancouver
Sato R, Vatic M, Peixoto da Fonseca GW, Anker SD, von Haehling S. Biological basis and treatment of frailty and sarcopenia. Cardiovascular Research. 2024;120(9):982-998. doi:10.1093/cvr/cvae073
BibTeX
@article{Sato2024,
author = {Sato, Ryosuke and Vatic, Mirela and Peixoto da Fonseca, Guilherme Wesley and Anker, Stefan D and von Haehling, Stephan},
title = {Biological basis and treatment of frailty and sarcopenia},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {9},
pages = {982--998},
doi = {10.1093/cvr/cvae073}
}
EUVIMED